Research Topics
Genomes and Genes | Rachel SchiffSummaryAffiliation: Baylor College of Medicine Country: USA Publications
| Collaborators
|
Detail Information
Publications
Proteomic analysis of tumor necrosis factor-alpha resistant human breast cancer cells reveals a MEK5/Erk5-mediated epithelial-mesenchymal transition phenotypeChanghua Zhou
Department of Chemistry, Xavier University of Louisiana, New Orleans, LA 70125, USA
Breast Cancer Res 10:R105. 2008....- Advances in breast cancer treatment and prevention: preclinical studies on aromatase inhibitors and new selective estrogen receptor modulators (SERMs)Rachel Schiff
The Breast Center, Department of Medicine, Baylor College of Medicine, Houston, TX, USA
Breast Cancer Res 5:228-31. 2003..Two recent studies in preclinical model systems that evaluate mechanisms of action of these new drugs and suggestions about their optimal clinical use are discussed... - Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate responseRachel Schiff
Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA
Clin Cancer Res 9:447S-54S. 2003..Thus, the interactions of these diverse elements are essential considerations in defining new predictive and therapeutic tools... - Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulatorsRachel Schiff
Department of Medicine, Baylor College of Medicine, Breast Center room N1230, One Baylor Plaza MS 600, Houston, TX 77030, USA
Cancer Chemother Pharmacol 56:10-20. 2005.... - Endocrinology and hormone therapy in breast cancer: new insight into estrogen receptor-alpha function and its implication for endocrine therapy resistance in breast cancerRachel Schiff
Breast Center, Baylor College of Medicine and The Methodist Hospital, Houston, Texas, USA
Breast Cancer Res 7:205-11. 2005..Preclinical data suggest that blockade of selected growth factor receptor signaling can overcome this type of resistance, and this strategy is already being tested in clinical trials... - Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistanceRachel Schiff
Breast Center, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA
Clin Cancer Res 10:331S-6S. 2004..We will also emphasize open questions and future challenges in the dynamic research field of molecular ER biology from the endocrine therapy perspective... - Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapyGrazia Arpino
Breast Center, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
J Natl Cancer Inst 99:694-705. 2007..We investigated whether blockade of all HER homo- and heterodimer pairs by combined treatment with several inhibitors could more effectively inhibit tumor growth in such models... - Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenograftsChad J Creighton
The Dan L Duncan Cancer Center, Baylor College of Medicine, Room N1230 02, One Baylor Plaza BCM 600, Houston, TX 77030, USA
Cancer Res 68:7493-501. 2008..Over time, the molecular phenotype of breast cancer can change... - Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistanceGrazia Arpino
Breast Center, Baylor College of Medicine, The Methodist Hospital, Houston, TX, USA
J Natl Cancer Inst 97:1254-61. 2005..As in laboratory models, lack of PR expression in ER+ tumors may be a surrogate marker of aberrant growth factor signaling that could contribute to the tamoxifen resistance observed in these tumors... - Estrogen-mediated down-regulation of E-cadherin in breast cancer cellsSteffi Oesterreich
The Breast Center, Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA
Cancer Res 63:5203-8. 2003..We propose that estrogen-mediated down-regulation of E-cadherin is a novel way of reducing E-cadherin levels in estrogen receptor-positive breast cancer... - Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancerJiang Shou
The Breast Center, Baylor College of Medicine, Houston, TX 77030, USA
J Natl Cancer Inst 96:926-35. 2004..Gefitinib's ability to eliminate this cross-talk and to restore tamoxifen's antitumor effects should be tested in the clinic... - Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinaseM Carolina Gutierrez
Breast Center and Department of Pathology, Baylor College of Medicine, Houston, TX, USA
J Clin Oncol 23:2469-76. 2005..CONCLUSION: The molecular pathways driving tumor growth can change as the tumor progresses. Crosstalk between ER, HER-2, p38, and ERK may contribute to tamoxifen resistance and may provide molecular targets to overcome this resistance... - Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapyXiaojiang Cui
Breast Center, Baylor College of Medicine, Houston, TX 77030, USA
J Clin Oncol 23:7721-35. 2005..Finally, we will consider the clinical implications of these observations... - Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancerC Kent Osborne
Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA
J Natl Cancer Inst 95:353-61. 2003.... - Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenograftsMothaffar F Rimawi
Lester and Sue Smith Breast Center, Margaret M and Albert B Alkek Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA
Clin Cancer Res 17:1351-61. 2011.... - Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancerChad J Creighton
Dan L Duncan Cancer Center, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
Breast Cancer Res 12:R40. 2010..We thus examined whether deregulated PI3K signaling in luminal ER+ breast tumors is associated with ER level and activity and intrinsic molecular subtype... - Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistanceGrazia Arpino
Dan L Duncan Cancer Center, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
Endocr Rev 29:217-33. 2008.... - Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancerC Kent Osborne
Breast Center, Baylor College of Medicine and The Methodist Hospital, One Baylor Plaza, BCM 600, Houston, TX 77030, USA
Breast 12:362-7. 2003..In turn, ER located in the cell membrane can activate the growth factor receptor pathways. Breast tumors with high levels of AIB1 and HER-2 may be resistant to tamoxifen because of an increase in its estrogen agonist activity... - Dominant-negative nuclear receptor corepressor relieves transcriptional inhibition of retinoic acid receptor but does not alter the agonist/antagonist activities of the tamoxifen-bound estrogen receptorAshby J Morrison
Department of Molecular and Cellular Biology and The Breast Center, Baylor College of Medicine, Houston, Texas 77030, USA
Mol Endocrinol 17:1543-54. 2003.... - The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growthJana Divisova
Department of Medicine, Breast Center, Baylor College of Medicine, Houston, TX 77030, USA
Breast Cancer Res Treat 98:315-27. 2006..This data supports previous studies indicating a role for GH/IGF in mammary gland development, and suggests that pegvisomant maybe useful for the prevention and/or treatment of estrogen receptor positive breast cancer... - Estrogen receptor positivity in mammary tumors of Wnt-1 transgenic mice is influenced by collaborating oncogenic mutationsXiaomei Zhang
Breast Center, Baylor College of Medicine, One Baylor Plaza, N1210 03, Houston, TX 77030, USA
Oncogene 24:4220-31. 2005..This is a first report of a mouse model of antiestrogen-resistant ER-positive breast cancers, and could provide a powerful tool to study the molecular mechanisms that control antiestrogen resistance... - Neoadjuvant trastuzumab induces apoptosis in primary breast cancersSyed K Mohsin
Breast Center at Baylor College of Medicine/The Methodist Hospital, 1 Baylor Plaza, MS 600, Houston, TX 77030, USA
J Clin Oncol 23:2460-8. 2005..02). CONCLUSION: In primary breast cancers, trastuzumab substantially induces apoptosis, providing a molecular explanation for both its therapeutic efficacy and its successful combination with cytotoxic chemotherapy... - Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancersBhuvanesh Dave
Lester and Sue Smith Breast Center, Dan L Duncan Cancer Center, Baylor College of Medicine, Houston, TX, USA
J Clin Oncol 29:166-73. 2011..Understanding of the cellular response to HER2-targeted therapies is needed to tailor treatments and to identify patients less likely to benefit... - Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancerC Kent Osborne
Breast Center, Baylor College of Medicine and The Methodist Hospital, Houston, Texas 77030 3798, USA
Clin Cancer Res 11:865s-70s. 2005..This process can be delayed or reversed by simultaneous treatment with growth factor pathway inhibitors. This strategy is now being tested in clinical trials... - A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesisJessica D Kessler
Verna and Marrs McLean Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, TX 77030, USA
Science 335:348-53. 2012..Thus, inhibition of SUMOylation may merit investigation as a possible therapy for Myc-driven human cancers... - Estrogen receptor beta protein in human breast cancer: correlation with clinical tumor parametersSuzanne A W Fuqua
Department of Medicine, Breast Center, Baylor College of Medicine, Houston, Texas 77030, USA
Cancer Res 63:2434-9. 2003..These results suggest that ERbeta expression is not a surrogate for ERalpha in clinical breast tumors and, as such, could be a useful biomarker in its own right... - Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II studyC Kent Osborne
Lester and Sue Smith Breast Center and Department of Pathology, Baylor College of Medicine, Houston, Texas 77030, USA
Clin Cancer Res 17:1147-59. 2011..This randomized phase II trial assessed tamoxifen plus placebo or the epidermal growth factor receptor inhibitor gefitinib in estrogen receptor (ER)-positive metastatic breast cancer... - Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancerLakshmi Sampath
Division of Molecular Imaging, Department of Radiology, Baylor College of Medicine, Houston, TX 77030, USA
J Nucl Med 48:1501-10. 2007..The stoichiometric ratios "n" and "m" refer to the number of diethylenetriaminepentaacetic acid dianhydride (DTPA) and IRDye 800CW molecules bound per trastuzumab molecule, respectively... - Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomesMothaffar F Rimawi
Department of Medicine, Baylor College of Medicine, Houston, TX, USA
Cancer 116:1234-42. 2010..We hypothesized that EGFR expression in human breast tumors, when centrally and uniformly assessed, is associated with an aggressive phenotype and resistance to systemic therapy... - Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunitiesSuleiman Massarweh
Department of Medicine, Markey Cancer Center, University of Kentucky, Lexington, Kentucky 40536, USA
Clin Cancer Res 13:1950-4. 2007.... - Endocrine responsiveness: understanding how progesterone receptor can be used to select endocrine therapyC Kent Osborne
The Breast Center, Baylor College of Medicine, One Baylor Plaza, BCM 600, Houston, TX 77030, USA
Breast 14:458-65. 2005.... - Estrogen-receptor biology: continuing progress and therapeutic implicationsC Kent Osborne
Breast Center, Baylor College of Medicine, One Baylor Plaza, BCM 600 Houston, TX 77030, USA
J Clin Oncol 23:1616-22. 2005 - Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalkSuleiman Massarweh
The Breast Center, Baylor College of Medicine, One Baylor Plaza, BCM 600, Houston, Texas 77030, USA
Endocr Relat Cancer 13:S15-24. 2006..Ongoing clinical trials of endocrine therapy combined with growth factor pathway inhibitors or their downstream signaling elements promise to further improve the present care for breast cancer patients... - Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphataseTingting Sun
Verna and Marrs McLean Department of Biochemistry and Molecular Biology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
Cell 144:703-18. 2011.... - Molecular profiles of progesterone receptor loss in human breast tumorsChad J Creighton
Dan L Duncan Cancer Center Division of Biostatistics, Baylor College of Medicine, Houston, TX 77030, USA
Breast Cancer Res Treat 114:287-99. 2009..Patient prognosis and response to endocrine therapy in breast cancer correlate with protein expression of both estrogen receptor (ER) and progesterone receptor (PR), with poorer outcome in patients with ER+/PR- compared to ER+/PR+ tumors... - ?1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinibCatherine Huang
Lester and Sue Smith Breast Center, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77054, USA
Breast Cancer Res 13:R84. 2011..The ?1 integrin resides on the membrane of the breast cancer cell, activating several elements of breast tumor progression including proliferation and survival... - Dual roles for coactivator activator and its counterbalancing isoform coactivator modulator in human kidney cell tumorigenesisYun Kyoung Kang
Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas 77030, USA
Cancer Res 68:7887-96. 2008..This is, thus far, the only example of a nuclear receptor coregulator involved in suppression of kidney cancer and suggests potentially significant new roles for coregulators in renal cancer biology... - Aromatase inhibitors: future directionsC Kent Osborne
Breast Center, Baylor College of Medicine and The Methodist Hospital, One Baylor Plaza, BCM 600, Houston, TX 77030, USA
J Steroid Biochem Mol Biol 95:183-7. 2005.... - Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growthYongmin Liu
Department of Medicine, Breast Center, Baylor College of Medicine, Houston Texas, TX 77030, USA
Oncogene 21:7680-9. 2002..These results suggest that novel agents specifically targeting AP-1 or its activating kinases could be promising agents for the treatment of breast cancer... - Somatic expression of PyMT or activated ErbB2 induces estrogen-independent mammary tumorigenesisMichael J Toneff
Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA
Neoplasia 12:718-26. 2010.... - Mechanisms of endocrine resistance in breast cancerC Kent Osborne
Dan L Duncan Cancer Center, Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA
Annu Rev Med 62:233-47. 2011..Results of recent clinical studies, while partly supporting this approach, also highlight the need to better identify a priori the patients whose tumors are most likely to benefit from these specific cotargeting strategies... - Immunoconjugated gold nanoshell-mediated photothermal ablation of trastuzumab-resistant breast cancer cellsLaura B Carpin
Department of Bioengineering, Rice University, 6100 Main St, MS 142, Houston, TX 77005, USA
Breast Cancer Res Treat 125:27-34. 2011..This study suggests potential for applying gold nanoshell-mediated therapy to trastuzumab-resistant breast cancers in vivo... - Different mechanisms for resistance to trastuzumab versus lapatinib in HER2- positive breast cancers -- role of estrogen receptor and HER2 reactivationYen Chao Wang
Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA
Breast Cancer Res 13:R121. 2011..Here we investigate resistance mechanisms to each drug alone, or to their combination using a large panel of HER2-positive cell lines made resistant to these drugs... - The dynamics of estrogen receptor status in breast cancer: re-shaping the paradigmSara Lopez-Tarruella
The Breast Center, Duncan Cancer Center, Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA
Clin Cancer Res 13:6921-5. 2007 - More on FOX News: FOXA1 on the horizon of estrogen receptor function and endocrine responseXiaoyong Fu
Lester and Sue Smith Breast Center, Baylor College of Medicine, One Baylor Plaza, BCM600, Houston, TX 77030, USA
Breast Cancer Res 13:307. 2011..The significance of FOXA1 in the chromatin interactions and transcriptional regulation of both estrogen- and tamoxifen-bound ER, and in supporting tamoxifen-resistant cell growth, may impact current endocrine therapies... - New mechanisms of signal transduction inhibitor action: receptor tyrosine kinase down-regulation and blockade of signal transactivationAdrian V Lee
Department of Medicine, Breast Center, Baylor College of Medicine, Houston, Texas 77030, USA
Clin Cancer Res 9:516S-23S. 2003..This review will highlight how recent studies using these STIs have elucidated novel mechanisms of STI action that may be used in the development of new therapeutic strategies for the treatment of cancer... - HER2: biology, detection, and clinical implicationsCarolina Gutierrez
Baylor College of Medicine, Department of Pathology, One Baylor Plaza, Houston, TX 77030, USA
Arch Pathol Lab Med 135:55-62. 2011..When shown to be overexpressed or amplified by appropriate methods, HER2 is a valuable treatment target... - Compartmentalized Ras proteins transform NIH 3T3 cells with different efficienciesChiang Min Cheng
Department of Molecular and Cellular Biology, Lester and Sue Smith Breast Center, 1 Baylor Plaza, Baylor College of Medicine, Houston, TX 77030, USA
Mol Cell Biol 31:983-97. 2011.... - The pINDUCER lentiviral toolkit for inducible RNA interference in vitro and in vivoKristen L Meerbrey
Verna and Marrs McLean Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, TX 77030, USA
Proc Natl Acad Sci U S A 108:3665-70. 2011..This feature allows isolation of cell populations that exhibit a potent, inducible target knockdown in vitro and in vivo that can be used in human xenotransplantation models to examine cancer drug targets... - Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancerSuleiman Massarweh
Department of Internal Medicine and Markey Cancer Center, University of Kentucky, Lexington, Kentucky, USA
Cancer Res 66:8266-73. 2006..Combining endocrine therapy with EGFR/HER-2/neu inhibitors should be tested in clinical breast cancer, but a more complete blockade of EGFR/HER-2/neu may be optimal... - Proceedings of the Third International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statementSteven E Come
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
Clin Cancer Res 10:327S-330S. 2004 - Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic functionSuleiman Massarweh
Department of Internal Medicine, Markey Cancer Center, University of Kentucky, Lexington, Kentucky, USA
Cancer Res 68:826-33. 2008..This study provides a rationale to combine HER inhibitors with tamoxifen in clinical studies, even in tumors that do not initially overexpress EGFR/HER2... - Estrogen dendrimer conjugates that preferentially activate extranuclear, nongenomic versus genomic pathways of estrogen actionWilliam R Harrington
University of Illinois, Department of Molecular and Integrative Physiology, 524 Burrill Hall, 407 South Goodwin Avenue, Urbana, Illinois 61801-3704, USA
Mol Endocrinol 20:491-502. 2006.... - Upregulation of PKC-delta contributes to antiestrogen resistance in mammary tumor cellsSanaa M Nabha
Department of Pathology, Wayne State University School of Medicine, 540 E Canfield, Detroit, MI 48201, USA
Oncogene 24:3166-76. 2005..05). Taken together, these data suggest that PKC-delta plays a major role in antiestrogen resistance in breast tumor cells and thus provides a new target for treatment...